G'morning! Stop by poster C6 at #PallOnc18--let's talk about polypharmacy at end of life in older adults! Thanks to the Plein Endowed Research Fund @UW_Pharmacy for supporting this work! #gerionc#deprescribing @zacharyamarcum
Community and academic oncologists’ perception of barriers to #clinicaltrialenrollment of older adults with cancer
#SIOG18 let’s fix this issue with a deeper understanding of the problem @minasedrakmd
Steroid treatment of immune mediated adverse effects do not impact overall efficacy when using immunotherapy in oncology.
If steroids, >20mg prednisone equivalent, are used for more than 4 weeks then consider PJP/PCP prophylaxis.
#siog18#GeriOnc
@minasedrakmd at #SIOG18
What are the barriers for enrollment of older adults with cancer in clinical trials?
Study of 44 US medical oncologists. @cityofhope
Brilliant presentation on the safety of checkpoint inhibitors on elderly cancer patients by Dr Baldini. Increased risk of grade 2+ immune-related adverse events. @CapuBaldini#SIOG18
@minasedrakmd Overly restrictive exclusion criteria and concern re: tx toxicity cited by physicians as main barriers to accrual of older pt with cancer to clinical studies #SIOG18#gerionc
@minasedrakmd academic med oncs consider physician bias and lack of time/support while community med oncs perceive pt attitudes and caregiver burden as barriers to accrual of older pt with cancer to studies #SIOG18#gerionc
@yaninchavarri at #SIOG18 Significant number of older women with triple negative breast cancer tested positive for breast cancer associated mutations. #bcsm
Exclusion from genetic testing on the basis of age alone does not appear to be justified. #gerionc